Author

Hanny T. Al-Samkari

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Sep 2026

Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Findings support mitapivat as the first oral disease-modifying therapy for adults with transfusion-dependent α-thalassaemia or β-thalassaemia, providing a new treatment option to reduce transfusion burden in this patient population.

M. Cappellini, Sujit Sheth, A. Taher et al. · The Lancet · 3 citations

Review Oct 2026

Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration.

Advances in the treatment of thalassaemia have led to major improvements in survival and quality of life over the past 30 years. In addition to developments in stem-cell transplantation, transfusion safety, iron overload monitoring, and iron-chelation therapy, novel disease-modifying and gene therapies are also emergin...

Hanny T. Al-Samkari, F. Aboobacker, B. Andemariam et al. · The Lancet Haematology · 2 citations

Review Oct 2026

An evaluation of mitapivat for the treatment of non-transfusion-dependent alpha- and beta-thalassemia.

Non-transfusion-dependent thalassemia (NTDT) describes a group of inherited hemoglobin disorders characterized by hemolytic anemia and ineffective erythropoiesis. Although patients with NTDT do not require lifelong regular transfusions for survival, they are at a substantial risk of complications including iron overloa...

Aaron N. Cheng, Hanny T. Al-Samkari · Therapeutic delivery · 0 citations